Can Özgür Devrim, Turan Nazlı, Demir Özkay Ümide, Öztürk Yusuf
Anadolu University, Faculty of Pharmacy, Department of Pharmacology, 26470 Eskişehir, Turkey.
Anadolu University, Faculty of Pharmacy, Department of Pharmacology, 26470 Eskişehir, Turkey.
Life Sci. 2017 Dec 1;190:110-117. doi: 10.1016/j.lfs.2017.09.023. Epub 2017 Sep 20.
This study was planned to examine the antidepressant potency of gallic acid (30 and 60mg/kg), a phenolic acid widely distributed in nature, together with its possible underlying monoaminergic mechanisms.
Antidepressant-like activity was assessed using the tail suspension (TST) and the modified forced swimming tests (MFST). Locomotor activity was evaluated in an activity cage.
Administration of gallic acid at 60mg/kg reduced the immobility duration of mice in both the TST and MFST without any changes in the locomotor activity. The anti-immobility effect observed in the TST was abolished with pre-treatment of p-chlorophenylalanine methyl ester (an inhibitor of serotonin synthesis; 100mg/kg i.p. administered for 4-consecutive days), ketanserin (a 5-HT2A/2C antagonist; 1mg/kg i.p.), ondansetron (a 5-HT3 antagonist; 0.3mg/kg i.p.), α-methyl-para-tyrosine methyl ester (an inhibitor of catecholamine synthesis; 100mg/kg i.p.), phentolamine (non-selective alpha-adrenoceptor antagonist; 5mg/kg i.p.), SCH 23390 (a dopamine D1 antagonist; 0.05mg/kg s.c.), and sulpiride (a dopamine D2/D3 antagonist; 50mg/kg i.p.). However, NAN 190 (a 5-HT1A antagonist; 0.5mg/kg i.p.) and propranolol (a non-selective β-adrenoceptor antagonist; 5mg/kg i.p.) pre-treatments were ineffective at reversing the antidepressant-like effects of gallic acid.
The results of the present study indicate that gallic acid seems to have a dual mechanism of action by increasing not only serotonin but also catecholamine levels in synaptic clefts of the central nervous system. Further alpha adrenergic, 5-HT2A/2C and 5-HT3 serotonergic, and D1, D2, and D3 dopaminergic receptors also seem to be involved in this antidepressant-like activity.
本研究旨在考察没食子酸(30毫克/千克和60毫克/千克)的抗抑郁效力,没食子酸是一种广泛存在于自然界的酚酸,并探究其潜在的单胺能机制。
采用悬尾试验(TST)和改良强迫游泳试验(MFST)评估抗抑郁样活性。在活动笼中评估运动活性。
60毫克/千克的没食子酸给药可减少小鼠在TST和MFST中的不动时间,且运动活性无任何变化。TST中观察到的抗不动效应在预先给予对氯苯丙氨酸甲酯(一种血清素合成抑制剂;腹腔注射100毫克/千克,连续给药4天)、酮色林(一种5-HT2A/2C拮抗剂;腹腔注射1毫克/千克)、昂丹司琼(一种5-HT3拮抗剂;腹腔注射0.3毫克/千克)、α-甲基-对酪氨酸甲酯(一种儿茶酚胺合成抑制剂;腹腔注射100毫克/千克)、酚妥拉明(非选择性α-肾上腺素能受体拮抗剂;腹腔注射5毫克/千克)、SCH 23390(一种多巴胺D1拮抗剂;皮下注射0.05毫克/千克)和舒必利(一种多巴胺D2/D3拮抗剂;腹腔注射50毫克/千克)后被消除。然而,预先给予NAN 190(一种5-HT1A拮抗剂;腹腔注射0.5毫克/千克)和普萘洛尔(一种非选择性β-肾上腺素能受体拮抗剂;腹腔注射5毫克/千克)不能逆转没食子酸的抗抑郁样作用。
本研究结果表明,没食子酸似乎具有双重作用机制,不仅可增加中枢神经系统突触间隙中的血清素水平,还可增加儿茶酚胺水平。此外,α肾上腺素能、5-HT2A/2C和5-HT3血清素能以及D1、D2和D3多巴胺能受体似乎也参与了这种抗抑郁样活性。